Assessment Of
Anti-Inflammatory Effect Of 830nm Laser Light Using
C-Reactive Protein
Levels
Freitas AC, Pinheiro AL, Miranda P, Thiers FA,
Vieira AL.
Department of Oral and Maxillofacial Surgery,
Faculty of Dentistry, PUC-RS, Porto
Alegre, RS, Brazil. Braz Dent J. 2001;12(3):187-90
The anti-inflammatory effect of non-surgical
lasers has been proposed previously, however it was
not scientifically proven. One method to assess
levels of inflammation is the measurement of
Creactive protein (CRP), which is increased with the
course of inflammation. The aim of this study was to
assess the effect of 830 nm laser irradiation after
the removal of impacted third molars using the CRP
as the marker of inflammation. Twelve patients were
irradiated with 4.8 J of laser light per session 24
and 48 h after surgery. A control group (N = 12) was
treated with a sham laser. Blood samples were taken
prior to, and 48 and 72 h after surgery. CRP values
were more symmetric and better distributed for the
irradiated group (0.320 mg/dl) than for the control
(0.862.mg/dl) 48 h after surgery, however there was
no statistically significant difference. After 72 h,
both groups had statistically similar CRP levels
(0.272 and 0.608 mg/dl), because of the
normal tendency of decreasing CRP levels.
Assessment Of Anti-Inflammatory Effect Of 830nm
Laser Light Using C-Reactive Protein Levels.
Braz Dent J.
2001;12(3):187-90.
Freitas AC, Pinheiro AL, Miranda P, Thiers FA,
Vieira AL.
Department of Oral and Maxillofacial Surgery,
Faculty of Dentistry, PUC-RS, Porto Alegre, RS,
Brazil.
The anti-inflammatory effect of non-surgical lasers
has been proposed previously,
however it was not scientifically proven. One method
to assess levels of inflammation is the measurement
of C-reactive protein (CRP), which is increased with
the course of inflammation. The aim of this study
was to assess the effect of 830 nm laser irradiation
after the removal of impacted third molars using the
CRP as the marker of inflammation.
Twelve patients were irradiated with 4.8 J of laser
light per session 24 and 48 h after
surgery. A control group (N = 12) was treated with a
sham laser. Blood samples were taken prior to, and
48 and 72 h after surgery. CRP values were more
symmetric and better distributed for the irradiated
group (0.320 mg/dl) than for the control
(0.862.mg/dl) 48 h after surgery, however there was
no statistically significant difference. After 72 h,
both groups had statistically similar CRP levels
(0.272 and 0.608 mg/dl), because of the normal
tendency of decreasing CRP levels.
RHEUMATOID arthritis
The Effects of Laser Therapy in the Early Stages of
Rheumatoid Arthritis Onset
C. Ailioaie, M. D. Medical Office for Laser Therapy,
Iassy, RO,
Laura Marinela Lupusoru-Ailioaie, M. D.
"Al.I.Cuza" University, Dept. of Medical Physics,
Iassy, RO
1.PURPOSE:´To study the effects of laser therapy, in comparison
with other modality trials (NSAIDs), at the onset of
(RA).
2.SUBJECTS and METHODS:
In the study 59 patients were included, in the first
6 - 12 months from RA onset. The patients were
divided into three groups: Group 1 (21 patients)
received laser therapy; Group 2 (18 patients) was
submitted to placebo laser therapy and NSAIDs
medication; Group 3 (20 patients) was treated only
with NSAIDs. Physical therapy was instituted in all
three groups. A GaAIAs diode laser (830 nm, maximum
output power 200 mW) was used. During 4 months,
courses of laser therapy - once daily for 8 days,
monthly – were administered to Group 1 and laser
placebo
Group 2. The density of energy (2 - 4 J/cm2) and
frequency (5 Hz or 10 Hz) were dependent on the
number and severity of pain in affected joints.
3.RESULTS:
The analysis of the clinical and biological
parameters at the end of treatment showed a
statistical significant decrease of duration of
morning stiffness of pain at rest and during
movements and improved acute phase reactants. The
overall efficacy rate in these studies was 86% in
group 1, 50% in the placebo laser group, and 40% in
group 3.
4.DISCUSSION and CONCLUSIONS:
After 4 months of treatment, our investigations
showed that infra-red laser therapy was able to
restore function, to relieve pain and to avoid the
complications of the disease or NSAIDs therapy
(digestive or renal) at RA onset, being the most
perspective modality of treatment.
INTRODUCTION
Rheumatic diseases are frequently multisystematic in
nature and chronic in duration. They represent the
clinical manifestations of chronic inflammation of
the tissues of the musculoskeletal system, blood
vessels, and skin. Rheumatoid Arthritis (RA) has a
great importance for medical practice, because it is
today the most frequent rheumatoid disease. Great
majority of autors agree that the main therapy in RA
is based on nosteroidal anti-inflammatory drugs (NSAIDs),
as the first group of drugs utilised all over the
World. Although very helpful in the most worrisome
involve the gastrointestinal tract and kidneys.
Recent experimental and clinical studies emphasise
that infrared laser rays of relatively low power
density, and wavelenghts which posses the greatest
penetrating capacity, have a major role on the cells
involved in the immune and inflammatory responses at
synovial membrane level. In the present study we
have investigated the effects of laser as a
non-medication therapy, comparatively with the
traditional NSAIDs trials, in an attempt to reveal
new pathogenic mechanisms of RA. In the period
1997-1998, 59 patients were included in the study
(from 19 to 62 years old), in the first 6-12 months
from RA onset.
The criteria of study were the following:
Clinical criteria:
arthritis with a 6-12 months onset, presence of
inflammatory synovial fluids, contracture of
dry-joints, tenosynovitis or bursitis, regional
muscular dystrophy, eventual ankylosis of joints in
the morning, acute or chronic iridocyclitis, fever,
myalgia. The diagnosis for RA was according to ARA
criteria.
The functional indices for assessment of pain and
joint inflammation were the following:
Tumefaction of joints was evaluated on a 3-degrees
scale (0 = joint without tumefaction; 1= moderate
tumefaction; 2 = severe tumefaction); Pain by
movement of joints was evaluated on a 4-degrees
scale (0 = without pain; 1=slight pain;
2 = moderate pain; 3 = severe pain); Severity of
movement's amplitude was evaluated on a 5-degrees
scale (0 = without loss of movement; 1 = 25%
limitation of movement; 2 = 50% limitation of
movement; 3 = 75% limitation of movement; 4 = total
loss of movement);
Laboratory criteria:
blood indices (haemoglobina, leukocytes, platelets,
serum immunoglobulins,
rheumatoid factor, erythrocyte sedimentation rate [ESR]
and C-reactive protein, T lymphocytes, NK cells =
natural killer cells), synovial biopsy specimens and
synovial fluid analysis.
Radiological criteria:soft
tissue swelling, osteoporosis and periarticular
osteopenia, cartilage narrowing, carpal and other
erosions, growth changes and synovial inflammatory
activity - were analysed on conventional plain films
and by Magnetic Resonance Imaging (MRI). X-rays
radiographs taken in the early stages of the
rheumatoid arthritis indicated no visible or minor
changes, in conformity to Steinbrocker criteria. MRI,
performed with a GIROSCAN T5 II, was a useful
diagnostic modality at patients with painful joints.
MRI - determined synovial membrane volumes were
correlated with the overall histological assessment
of synovial inflammatory activity.
Other examinations:
ophtalmological examination (routine slit lamp
examination); X-rays diagnosis eso-gastro-duodenal;
fibroscopic examination; renal and hepatic
functional probes.
The patients were divided into 3 groups: Group 1 (21
patients) received laser therapy; Group 2 (18
patients) was submitted to placebo laser therapy and
NSAIDs medication; Group 3 (20 patients) was treated
only with NSAIDS.
It has been used a GaAIAs diode laser (830 nm,
maximum output power 200 mW). During 4 months,
courses of laser therapy - once daily for 8 days,
monthly - were administered to Group 1 and laser
placebo Group 2. The density of energy (2-4 J/cm2)
and frequency (5 Hz or 10 Hz) were dependent on the
number and severity of pain in affected joints.
The initial treatment with NSAIDS in Groups 2 and 3
was prescribed with Diclofenac, without exceeding
150 mg/day - in two doses - in the morning and in
the afternoon, after meals. In the protocol of
treatment were included, as adjuvant medication for
the relief of severe pain:
Panadeine (1 - 3 tablets/day), Mydocalm (1 - 3
tablets/day) Calcium and vitamins. Clinical features
and laboratory findings were evaluated before the
treatment and after 4 months of treatment. The
patients were clinically re-evaluated after one year
from the beginning of the treatment. The selected
parameters were analysed with Student's test.
RESULTS
Analysing the 3 groups of patients diagnosed with RA
under consideration, it comes out that there were no
important differences as concerns the clinical and
biological features at the beginning of trestment
(Table 1).
Because the synovial membrane is the primary site of
inflammation in joints with RA, there were performed
synovial biopsies in 4 patients from Group 1; the
overall historical assessment of chronic synovitis
was well correlated with MRI - determined synovial
membrane's aspect, being possible to exclude the
knee tuberculosis. MRI presents significant
advantages for non-invasive diagnosis of RA, and
proved accuracy by patients with paintful knee, no
visible modified X-rays radiographs and slightly
increased acute phase reactants (Figure 1 ).
After 4-months trial of treatment, we noticed that
86% of the patients from Group 1 were going to
respond well and to experience a favourable outcome,
in comparison with 50% of the patients from Group 2,
and only 40% from Group 3, respectively. By these
patients, we remarked the decrease of the number of
swelling joints and pain, an improved duration of
morning stiffness and better preservation of joint
function.
The laser radiation made possible not only the
optimum treatment in pain-reduction therapy, but
also get an improvement and/or a recovery of
patients. The laser therapy had a direct influence
on the immune system by increasing the number of NK
lymphocytes, while T lymphocytes remained
quantitavely unmodified, but possibly with a better
function (Table 2).
Clinical evaluation of the patients after one year
enabled us to conclude about the efficacy of
treatment in the three groups. The remission was
achieved in the greatest percentage (76%) by the
patients of Group 1, in comparison with Groups 2 and
3, which did not receive laser therapy.
In all three groups there were patients with active
arthritis, but the smallest percentage (10%) was
obtained in Group 1, which demonstrates a greater
effectiveness of laser therapy in comparison with
the NSAIDs-therapy. In Groups 2 and 3, the patients
have manifested adverse reaction to NSAIDs -
therapy. The serious side effects were reactions
cutaneous hypersensitivity, gastrointestinal
reaction, renal and hepatic reactions (Table 4).
DISCUSSIONS
The treatment with soft lasers that operate on mW
power level has substantially reduced the systemic
and local clinical symptomatology, in a very good
agreement with the evolution of the biological
features in the Group 1.
The influence of laser on the immune system has been
evidenced in medical literature; immunological
effects on leukocytes, T, B and NK-lymphocytes,
macrophages and other cells result in local and
systemic effects through a complex mechanism of
actions, which is not yetdefinitively elucidated.
We proposed in figure 2, a scheme to explain our
clinical and biological results of the applied laser
therapy. We consider that in the early stages of RA
onset, laser irradiation of synovial membrane could
directly control the autoimmune mechanism by
reducing the local and systemic
inflammatory response (Figure 2).
MRI of the synovial membrane performed in our
experiments was able to visualize the specific laser
therapeutic response. The new MRI techniques can
perform extremely sophisticated examinations and
will monitor in the future, arthritis at its onset.
The obtained effects of laser therapy, have revealed
the special quality of laser beam to interact with
cells, to determine a controlled biochemical
conversion of energy and to influence the cellular
metabolism in RA, as is proposed in figure 3. We
present a functional diagram, which could explain
the interactive laser mechanisms at membrane level
and its action on the up-mentioned metabolism
(Figure 4)
CONCLUSIONS
Laser radiation made possible not only the optimum
treatment in pain reduction therapy, but also
brought an improvement and recovery of patients,
demonstrating the greatest effectiveness, in
comparison with NSAIDs therapy in the early stages
of RA onset.
MRI of the synovial membrane performed in our
experiments was able to visualize the specificlaser
therapeutic response and in the future will
facilitate the monitoring of arthritis at its onset.
The laser therapy had a direct influence on the
immune system by controlling the number of
lymphocytes and improving their function. Even the
action mechanism is very complex, the laser therapy
is the most perspective method of today
non-medication therapy.
TABLES
The Effect Of Laser Therapy In Complex Treatment Of
Patients With Rheumatoid Arthritis.
Korolkova O M et al.
115 patients with rheumatoid arthritis (RA) of
II-III degrees were treated with basic RA
medications and infrared laser. In a control group
of 20 patients only basic medication was given.
10 areas of the body were irradiated daily,
increasing the dose every day during a period of
8-10 days. The effectiveness of the therapy was
controlled through laboratory tests on i.a.
inflammatory agents and the activity of lipid
peroxidation. The results were statistically
significant.
The best effect was found in patients with degree II
RA. Steroid medication could be reduced 8- 10 days
earlier in this group of patients and in some cases
the medication could even be excluded. Degree III
patients had a more moderate benefit of the laser
treatment.
The Interauricular Laser Therapy Of Rheumatoid
Arthritis.
Interaurikuliarnaia lazernaia terapiia revmatoidnogo
artrita. Sidorov-V-D, Mamiliaeva-D-R, Gontar-E-V,
Reformatskaia-SIu.
Vopr-Kurortol-Fizioter-Lech-Fiz-Kult.
1999; (3): 35-43.
Investigations have proved the ability of
interauricular low- intensity infrared laser therapy
(0.89 nm, 7.6 J/cm) to produce anti- inflammatory,
immunomodulating action in patients with rheumatoid
arthritis. The method has selective,
pathogenetically directed immunomodulating effect
the mechanism of which is similar to that of basic
antirheumatic drugs and of intravenous laser
radiation of blood. This laser therapy can be used
as an alternative to intravenous blood radiation
being superior as a noninvasive method.
Interauricular laser therapy can potentiate the
effects of nonsteroid anti-inflammatory drugs,
cytostatics and diminish their side effects.
Clinical Application Of GaAiAs 830 Nm Diode Laser In
Treatment Of Rheumatoid Arthritis
Kanji Asada, Yasutaka Yutani, Akira Sakawa and Akira
Shimazu. Department of Orthopaedic Surgery, Osaka
City University Medical School, Japan
The authors have been involved in the treatment of
rheumatoid arthritis (RA), in particular chronic
poly-arthritis and the associated pain complaints.
The biggest problem facing such patients is joint
contracture, leading to bony ankylosis. This in turn
severely restricts the range of motion (ROM) of the
RA-affected joints, thereby seriously restricting
the patient's quality of life (QOL).
The authors have determined that in these cases,
daily rehabilitation practice is necessary to
maintain the patient's QOL at a reasonable level.
The greatest problem in the rehabilitation practice
is the severe pain associated with RA-affected
joints, which inhibits restoration of mobility and
improved ROM. LLLT or low reactive level laser
therapy has been recognized in the literature as
having been effective in pain removal and
attenuation. The authors accordingly designed a
clinical trial to assess the effectiveness of LLLT
in RA related pain (subjective self-assessment) and
ROM improvement (objective documented data).
From July 1988 to June 1990, 170 patients with a
total of 411 affected joints were treated using a
GaAlAs diode laser system (830 nm, 60 mW C/W).
Patients mean age was 61 years, with a ratio of
males: females of 1: 5.25 (16%: 84%). Effectiveness
was graded under three categories: excellent
(remarkable improvement), good (clearly apparent
improvement), and unchanged (little or no
improvement). For pain attenuation, scores were:
excellent; 59.6%; good;30.4%; unchanged;10%.
For ROM improvement the scores were:
excellent;12.6%; good;43.7%; unchanged;43.7%. This
gave a total effective rating for pain attenuation
of 90%, and for ROM improvement of 56.3%.
Lasers Surg Med 1980;1(1):93-101
Laser Therapy Of Rheumatoid Arthritis
Goldman JA, Chiapella J, Casey H, Bass N, Graham J,
McClatchey W, Dronavalli RV, Brown R,
Bennett WJ, Miller SB, Wilson CH, Pearson B, Haun C,
Persinski L, Huey H, Muckerheide M
Thirty people with classical or definite rheumatoid
arthritis received laser exposure to a Q-switch
neodymium laser that operated at 1.06 micrometer
with an output of 15 joules/cm2 for 30 nsec.
One hand was lased at the proximalinterphalangeal
(PIP) and metacarpal phalangeal (MCP) joints,
whereas the other hand was sham lased. The patient,
physician, and occupational therapy evaluators did
not know which hand was being lased. Twenty-one
patients noted improvement ofboth their MCP and PIP
joints of both hands during laser therapy.
Twenty-seven noted improvement of their PIP joints
and 26 noted improvement of the MCP joints during
therapy.
Heat, erythema, pain, swelling, and tenderness all
improved with time in both hands, but the lased hand
had more significant improvement in erythema and
pain. There was also significant improvement in
grasp and tip pressure on the lased side. The level
of circulating immune complexes as measured by
platelet aggregation decreased during lasing. The
improvement may be related to laser exposure. The
exact role that laser radiation has upon rheumatoid
arthritis and its mechanism of action remain poorly
understood.
Laser Therapy In Rheumatology
Judit Ortutay M.D., Klara Barabas M.D., Ph.D., *Adam
Mester MD National Institute ofRheumatology and
Physiotherapy, Budapest *Semmelweis University,
Faculty of Medicine, Dept. of Diagnostic Radiology
and Oncotherapy, National Laser Therapy Centre,
Peterfy Sandor, Teaching Hospital, Budapest
Barabas irradiated first the joints of rheumatoid
arthritis (RA) patients without skin ulcer. In the
first open study objectively the range of motion and
circumference of the treated joints were measured,
Ritchie index as semiobjective parameter, subjective
parameters as joint tenderness and pain on a visual
analogous scale (VAS) were registered. The walking
time was registered as a functional disability
parameter. Laboratory activity parameters and the
99mTechnetium index was measured. The second part of
the clinical study was double blinded, Infra Red
(10mW and 100 mW) lasers were used versus dummy
devices with the same outlook. The third part of the
study were in vitro experiments. Synovial membranes
of rheumatoid arthritis patients The DNA/RNA ratio
of the RA group was compared to the control group.
Significant difference was detected between the two
groups. The fourth phase of clinical studies was to
detect the effects of laser irradiation in other
rheumatic diseases: psoriatic arthritis,
sacroileitis, osteoarthritis, entesopathy,
tenosynovitis, bursitis calcarea, fibromyalgia,
localised muscle spasm, periarthritis
humeroscapularis etc.
The different wavelengths (604, 630, 660, 670, 690,
750, 780, 790, 820, 830, 904, 1053, 1219 nm,) were
compared (30 - 100 mW) with other physiotherapy
modalities, like ultrasound.
Acknowledgement: The Central Research Institute of
the Hungarian Academy of Sciences and Cochrane
Database Syst Rev. 2000;(2):CD002049.
Low Level Laser Therapy (Classes I, II And III) In
The Treatment Of Rheumatoid Arthritis
Brosseau L, Welch V, Wells G, deBie R, Gam A, Harman
K, Morin M, Shea B, Tugwell P.
School of Rehabilitation Sciences, Faculty of Health
Sciences, University of Ottawa, 451 Smyth Road,
Ottawa, Ontario, Canada, K1H-8M5. lbrossea@uottawa.ca
BACKGROUND:
Rheumatoid arthritis (RA) affects a large proportion
of the population.
Low
Level Laser Therapy (LLLT) was introduced as an
alternative non-invasive treatment for RA about 10
years ago. LLLT is a light source that generates
extremely pure light, of a single wavelength. The
effect is not thermal, but rather related to
photochemical reactions in the cells. The
effectiveness of LLLT for rheumatoid arthritis is
still controversial. OBJECTIVES: To assess the
effectiveness of LLLT in the treatment of RA.
SEARCH STRATEGY:
We searched MEDLINE, EMBASE, the registries of the
Cochrane Musculoskeletal group and the field of
Rehabilitation and Related Therapies as well as the
Cochrane Controlled Trials Register up to January
30, 2000.
SELECTION CRITERIA:
Following an a priori protocol, we selected only
randomized controlled trials of LLLT for the
treatment of patients with a clinical diagnosis of
RA were eligible. Abstracts were excluded unless
further data could be obtained from the authors.
DATA COLLECTION AND ANALYSIS:
Two reviewers independently select trials for
inclusion, then extracted data and assessed quality
using predetermined forms. Heterogeneity was tested
with Cochran's Q test. A fixed effects model was
used throughout for continuous variables, except
where heterogeneity existed, in which case, a random
effects model was used.
Results
were analyzed as weighted mean differences (WMD)
with 95% confidence intervals (CI), where the
difference between the treated and control groups
was weighted by the inverse of the variance.
Standardized mean differences (SMD) were calculated
by dividing the difference between treated and
control by the baseline variance. SMD were used when
different scales were used to measure the same
concept (e.g. pain). Dichotomous outcomes were
analyzed with odds ratios.
MAIN RESULTS:
A total of 204 patients were included in the five
placebo-controlled trials, with 112 randomized to
laser therapy. Relative to a separate control group,
LLLT reduced pain by 70% relative to placebo and
reduced morning stiffness duration by 27.5 minutes
(95%CI: 2.9 to 52 minutes) and increased tip to palm
flexibility by 1.3 cm (95% CI: 0. 8 to 1.7 cm).
Other outcomes such as functional assessment, range
of motion and local swelling did not differ between
groups. There were no significant differences
between subgroups based on LLLT dosage, wavelength,
site of application or treatment length. For RA,
relative to a control group using the opposite hand,
there was no difference between the control and
treatment hand, but all hands improved in terms of
pain relief and disease activity.
REVIEWER'S CONCLUSIONS:
In summary, LLLT for RA is beneficial as a minimum
of a fourweek treatment with reductions in pain and
morning stiffness. On the one hand, this
metaanalysis sound that pooled data gave some
evidence of a clinical effect, but the outcomes were
in conflict, and it must therefore be concluded that
firm documentation of the application of LLLT in RA
is not possible. Clinicians and researchers should
consistently report the characteristics of the LLLT
device and the application techniques used. New
trials on LLLT should make use of standardized,
validated outcomes. Despite some positive findings,
this meta-analysis lacked data in how LLLT
effectiveness is affected by four important factors:
wavelength, treatment duration of LLLT, dosage and
site of application over nerves instead of joints.
The Use Of Supravascular Blood Radiation With
Infrared Laser For Treatment Of Secondary Vasculitis
In Patients With Rheumatoid Arthritis
Y.L. Grinstein, S.V. Ivlev, Medical Academy.
Krasnoyarsk, Russia
The purpose of this work was to study the
opportunity of the use of supravascular blood
radiation with infrared laser (IR-laser) for the
treatment of secondary vasculitis in patients with
rheumatoid arthritis (RA). The investigation
included 12 patients with RA and secondary
vasculitis signs.
They
received a course of supravascular blood radiation
with IR-Iaser (wavelength 820-850 nm, 7-10
procedures). Control group consisted of 8 patients.
Placebo laser therapy (LT) was administered to 7
patients. Such characteristics as hemostasis
properties, a state of microcirculation in bulbar
conjunctiva vessels were studied in all patients
before and after treatment.
It
was revealed
significant decrease of both XIIa-depended
fibrinolysis and Willibrand's factor level. The
improvement of blood rheological properties was
confirmed by a decrease of erythrocyte aggregation
and im-provement of its deformability.
Bulbar conjunctival microscopia revealed
significant diminution of intravascular change
index, significant increase of arteriola-venula
ratio.
The improvement of nephritis manifestations
(significant decrease of proteinuria level). The
changes of hemostasis parameters microcirculation
system were not significant in patients receiving
both placebo LT and conventional therapy.
Conclusions:
1) It was revealed significant diminution of
endothelium lesion and XIla-depended fibrinolysis
restoration after IR-laser therapy in patients with
RA and secondary vasculitis.
2)
Both
micro-circulation state in bulbar conjunctiva
vessels and blood rheological properties
significantly improve after IR-laser therapy. It is
confirmed by a significant improvement of
erythrocyte deformability and a decrease of its
aggregation. 3) IR-laser therapy leads to urinary
syndrome regression.
Diagnostic Significance Of The Immunity Indices
Investigation In The Use Of Laser Therapy In
Patients With Rheumatoid Arthritis And The Disease
Course Prognosis
A.V. Nikitin, V.D. Khvan, E.F. Yevstratova,
Medical Academy, Voronezh, Russia
The results of the examination of the patients with
rheumatoid arthritis (RA) have shown the systemic
lesion of all the links of the immune system.
Many-sided positive influence of low energy laser
irradiation on the impairment of immune homeostasis
has been shown. The aim of the investigation was to
study the possibility of the low energy laser
irradiation use in patients with RA depending on
some immunity indices and the disease course
prognosis. 60 patients with RA at the age of more
than 16 years old having inflammatory process
activity of the I-II degrees according to the RA
criteria of the American Rheumatological Association
classification have been examined. 30 patients of
the control group underwent the conventional
treatment with nonsteroid anti-inflammatory drugs,
basic treatment with delagil and physiotherapy. 30
patients of the main group underwent the
conventional treatment and laser therapy on the
joints by the infrared laser installation "UZOR"
with the wavelength of 0,89 um, the output power of
2 mW in combination with the above-vein blood
irradiation by the helium-neon laser installation
"ALOK-1" with the output power of 0,6 mW. The
treatment was carried out daily during 15 days. The
immunity indices analysis before and after the
treatment in both groups has established their
obvious improvement in patients treated by laser
irradiation:
T-lympocytes
(CD3 (p<0.05), immunoglobulins ?
(p<0.05), T-helpers inductors (CD4+) (p<0.05).
The positive dynamics of the immunity indices in the
studied group correlated with the clinical
improvement of the patients condition and depended
on the marked immunity indices changes before the
treatment, such as T-lymphocytes (CD3), T-helpers
inductors (CD4+),
immunoglobulins C. The marked
|